Member Info for mizman

Just confirmed, they are in the very final stages.

MOU between the consortium being finalised now, as technically its lapsed.

When it's released, we will find out exactly how much of that £13, Omega will keep. Next will be news rich and explosive.

?

We will get a trading update next week, so should get a couple of RNS's before that. I think we will be testing the 120+ range again.

Just got 1750 at 96.8 :)

Thanks MM.

Can't buy on HL

For traders, the % margin is getting narrower and chance of getting locked out of a substantial rise, greater.

If you sell so be it. I'm staying for the 2.5m tests production per week and and a £3 SP top slice.

There is a lot of hot money in NCYT and EUA.
When a couple of big RNS's land here, I would expect some of that will be headed to Omega.

The next rise here, hopefully will be be more steep and hold.

And here's a reply to my question from last week:


"Turner Pope are not a broker to Omega and so this doesn’t herald a fundraise, they simply invited Omega to talk about the various opportunities they have (CD4, Food Intolerance, COVID-19) to their investor base. One of ODX’s major investors knows the TPI team well and suggested that they might want to tell their story to a wider audience of investors (i.e. TPI’s client base of high net worth individuals and other investors)."
So let's put this fear of placing to bed.

Safy, no it was Wallbrook.

I asked this question of fund raise, for Colin's presentation to institutional investors. He denied it, as the presentation was at their request.

Yes and they've used the Fincap note as the catalist, despite yesterday's good RNA. Question is, are Fincap in on it?

Anyway, we are going to produce 2.5m tests per week. This is heading towards £2 and beyond, very soon. Keep that in mind, when these shenanigans occur.

No chance. Fully utilise current funds and generate revenue first.

Moonshot is all about rapid non lab based tests.

The UK has agreed to settle a lawsuit over how it selected an IT contract for coronavirus testing at its Lighthouse labs.

The BBC understands that the settlement will cost the government up to £2m.

British company Diagnostics AI claimed it lost out to a European rival UgenTec despite spotting some positive coronavirus cases its rival missed.

It sued the government over the decision, claiming the selection process was "unfair and unlawful".

Lighthouse labs are a UK-wide network of specialist coronavirus laboratories managed by the government and run by private firms. When the labs were set up, companies pitched to analyse the test results.

https://www.google.com/amp/s/www.bbc.co.uk/news/amp/business-54455666

Yes, we should get that in an RNS soon.

Remember, there will be a trading update around the 15th, so that RNS should be by next week.

This is part of his reply. May share more later.

A far more accurate overview of the potential of the business is actually in the 22 June 2020 note from finnCap.

In there you can see they highlight that 100% production capacity for Lateral Flow Tests and ELISA tests would generate very significant revenues and gross profits. This isn’t in their forecasts but shows the upside potential.

Yes. I have a feeling he won't like it.

Dear finnCap, here’s a real forecast for Omega Diagnostics earnings this financial year
October 8, 2020ShareBuyers Editorial Team
When house broker finnCap issued an updated broker note that Omega Diagnostics will receive paltry revenues of £5.7m until the end of the financial year from the UK RTC, it understandably sent alarm bells ringing.

Why would a house broker issue such a downbeat update on its own client many asked – excluding other revenue streams and proposed ramp ups in capacity.

We were also questioning as to why a leading AIM broker appears to be struggling to make a forecast with any degree of accuracy on its own client – Omega Diagnostics is not a complex business in terms of its structure or potential immediate opportunities.

Therefore, we decided to do a little quick number crunching of our own which should give finnCap a helping hand in understanding the general areas to hone in on when it comes to making a new forecast and giving investors the information they need. Our model below assumes the following:

There are 19 weeks remaining until Omega consolidates its financials
finnCap’s COVID-19 excluding revenue estimate of £12.6m is accurate. We assume it will make £1.6m net profit on this from historical margins.
A constant production of 200,0000 tests for the UK RTC for the next 19 weeks – receiving £1.50 per test with a net profit of 40%.
From week 10, Omega’s overall capacity increases to 500,000
From week 10, it produces 300,000 tests per week for Mologic or Avacta – receiving £4 per test with a net profit of 40%.
From week 14, Omega’s overall capacity increases to 1,000,000 tests per week
From week 14, Omega produces 800,000 tests per week for Mologic or Avacta – receiving £4 per test with a net profit of 40%.
General assumptions; the UK RTC held back how much it could charge, it will be charging Mologic / Avacta more for production. Demand will be there from Mologic or Avacta to fill capacity on a week-by-week basis.
So where does all of the above leave the revenue and profit from ODX by the end of the financial year potentially?

Revenue = £43.1m and Profit = £13.8m
Over to you finnCap…

https://www.sharebuyers.co.uk/shares/dear-finncap-here-is-a-real-omega-diagnostics-forecast/

For investors looking to understand more about the potential revenues and gross profits that could be achieved by Omega based on different capacity utilisation rates we would recommend looking at finnCap’s note from 22 June 2020 – this can also be accessed via the finnCap research library:

https://researchlibrary.finncap.com/User/Login



In this note you will see the analyst discusses the difficulty of forecasting potential COVID-19 revenues with any degree of accuracy. This is why finnCap’s target price remains under review although they do acknowledge that “the valuation upside is considered substantial.” Therefore the analyst provides an assessment of potential revenues and gross profits based on different capacity utilisation rates for production at the Alva facility.

Buy, buy. When we are producing 2.5m tests per week today's SP will be a bargain.